Table 3.
Clinicopathological characteristics and treatment outcomes of Double Protein Expression Lymphoma (DPL) and Triple Protein Expression Lymphoma (TPL).
| Clinical and pathological characteristics | DPL (MYC+/BCL2+) | TPL (MYC+/BCL2+/BCL6+) | ||||
|---|---|---|---|---|---|---|
| Positive | Negative | P value | Positive | Negative | P value | |
| Mean age, years (SD) | 60.3 (15.8) | 52.1 (14.7) | 0.048 | 54.1 (14.9) | 53.9 (13.4) | 0.810 |
| Age >60 years | 9/16 (56.2%) | 17/56 (30.3%) | 0.057 | 19/48 (39.5%) | 17/56 (30.3%) | 0.324 |
| Gender - Male | 7/16 (43.7%) | 27/56 (48.2%) | 0.752 | 30/48 (62.5%) | 27/56 (48.2%) | 0.144 |
| Diagnostic specimen sites | ||||||
| Lymph nodes | 8/16 (50.0%) | 23/56 (41.1%) | 0.288 | 21/48 (43.8%) | 23/56 (41.1%) | 0.165 |
| Waldeyer's ring | 1/16 (6.3%) | 6/56 (10.7%) | 10/48 (20.8%) | 6/56 (10.7%) | ||
| Extranodal sites | 7/16 (43.7%) | 27/56 (48.2%) | 17/48 (35.4%) | 27/56 (48.2%) | ||
| Subtype | ||||||
| GCB | 0/16 (0%) | 19/56 (33.9%) | 0.008 | 12/48 (25.0%) | 19/56 (33.9%) | 0.392 |
| Non-GCB | 16/16 (100%) | 37/56 (66.1%) | 36/48 (75.0%) | 37/56 (66.1%) | ||
| CD5 positive | 2/16 (12.5%) | 1/56 (1.7%) | 0.122 | 5/48 (10.4%) | 1/56 (1.8%) | 0.093 |
| EBER positive | 1/16 (6.25%) | 3/56 (5.3%) | 0.643 | 4/48 (8.3%) | 3/56 (5.4%) | 0.701 |
| c-Myc gene rearrangement | ||||||
| Positive | 3/16 (18.7%) | 2/56 (3.5%) | 0.020 | 2/48 (4.2%) | 2/56 (3.6%) | 0.631 |
| Extra copies | 1/16 (6.2%) | 0/56 (0%) | 0/48 (0%) | 0/56 (0%) | ||
| BCL2 gene rearrangement | ||||||
| Positive | 1/16 (6.2%) | 4/56 (7.1%) | 0.736 | 2/48 (4.2%) | 4/56 (7.1%) | 0.530 |
| Extra copies | 0/16 (0%) | 2/56 (3.5%) | 4/48 (8.3%) | 2/56 (3.6%) | ||
| BCL6 gene rearrangement | ||||||
| Positive | 2/16 (12.5%) | 8/56 (14.2%) | 0.610 | 7/48 (14.5%) | 8/56 (14.3%) | 0.591 |
| IPI > 2 | 9/16 (56.2%) | 19/56 (33.9%) | 0.106 | 22/48 (45.8%) | 19/56 (33.9%) | 0.234 |
| LDH - Raised | 11/16 (68.7%) | 41/56 (73.2%) | 0.635 | 37/48 (77.1%) | 41/56 (73.2%) | 0.821 |
| Stage - III, IV | 10/16 (62.5%) | 29/56 (51.7%) | 0.448 | 29/48 (60.4%) | 29/56 (51.8%) | 0.431 |
| Treatment outcome - CR rate | ||||||
| RCHOP-like | 2/6 (33.3%) | 19/30 (63.3%) | 0.210 | 20/28 (71.4%) | 19/30 (63.3%) | 0.512 |
| CHOP-like | 3/6 (50.0%) | 5/16 (31.2%) | 0.732 | 1/12 (8.3%) | 5/16 (31.2%) | 0.254 |
| Treatment outcome - 2-year survival rate | ||||||
| RCHOP-like | 3/6 (50%) | 22/30 (73%) | 0.080 | 22/28 (78%) | 22/30 (73%) | 0.053 |
| CHOP-like | 3/6 (50%) | 10/16 (62%) | 0.089 | 2/12 (16%) | 11/16 (68%) | 0.002 |
| Treatment Outcome - median OS (IQR) (month) | ||||||
| RCHOP-like | 17.7 (20) | 29.8 (15) | 0.080 | 22.6 (17) | 29.8 (15) | 0.053 |
| CHOP-like | 19.6 (19) | 27.6 (13) | 0.089 | 14.1 (16) | 27.6 (13) | 0.002 |
CR: complete response; EBER: Epstein-Barr virus encoded ribonucleic acid; GCB: germinal center B-cell; IQR: interquartile range; LDH: lactate dehydrogenase; OS: overall survival; SD: standard deviation